We tested the hypothesis that cyclooxygenase (COX), thromboxane A 2 synthase (TxA 2 -S), thromboxane prostanoid receptors (TP-Rs), or superoxide anion (O 2 Ϫ ) mediates enhanced contractions of renal afferent arterioles (Aff) of angiotensin II (Ang II)-infused rabbits. Rabbits were infused with vehicle (sham), Ang II 60 ng⅐kg Ϫ1 ⅐min Ϫ1 (Ang II 60) or 200 ng⅐kg Ϫ1 ⅐min Ϫ1 (Ang II 200). There was a selective enhanced vasoconstriction of Affs from Ang II 60 rabbits to Ang II (⌬diameterϪ78Ϯ8% versus Ϫ43Ϯ9%; PϽ0.01) that was normalized by a TP-R antagonist but not by a superoxide dismutase (SOD) mimetic. Affs from Ang II 200 rabbits had increased (PϽ0.01) mRNA for COX-2 and enhanced vasoconstriction to Ang II, U-46 619 (TP-R mimetic), and endothelin-1 that was normalized by ifetroban plus tempol together. Endothelium removal enhanced Ang II responses of Affs from sham rabbits but blunted responses from Ang II 200 rabbits and abolished responses to ifetroban. Affs from Ang II 200 rabbits had an endothelium-dependent contraction factor (EDCF) response to that was blunted (PϽ0.001) by a SOD mimetic or antagonists of COX-1 or TxA 2 -S but normalized by antagonists of COX-2 or TP-R. Thus, enhanced Ang II responses in Affs from rabbits infused with slow pressor Ang II are mediated independently by O 2 Ϫ in the vascular smooth muscle cells and by an EDCF that is principally a vasoconstrictor prostaglandin generated by COX-2 ϾϪ1 activating TP-Rs, whereas enhanced responses in rabbits infused with a lower Ang II dose are dependent on TP-R but not O 2 Ϫ .
P rolonged infusion of angiotensin II (Ang II) at an initially subpressor rate into mice, rats, rabbits, or humans gradually increases blood pressure. [1] [2] [3] [4] This "slow pressor" response increases renal vascular resistance before hypertension and increases reactivity of the afferent arterioles (Affs) to Ang II in vitro and in vivo. 3, 5, 6 The slow pressor response activates nicotine adenine dinucleotide phosphate (NADPH) oxidase. 7 In contrast, rats infused with norepinephrine (NE) do not have oxidative stress or enhanced NADPH oxidase. 8 The hypertension and renal vasoconstriction depend on superoxide anion (O 2 Ϫ ) because they are prevented by tempol (4-hydroxy-2, 2,3,6-tetramethyl piperidinoxyl), which is a permeant nitroxide superoxide dismutase (SOD) mimetic. 3, 9, 10 There is increased expression in Affs of the p22 phox 11 and increased renal cortical NADPH oxidase activity. 6, 11 The slow pressor response is accompanied by an increased excretion of prostaglandins (PGs) and thromboxane A 2 (TxA 2 ) metabolites. [12] [13] [14] It is not seen in thromboxane prostanoid receptor (TP-R) knockout mice and is blunted by an antagonist of TP-R or thromboxane A 2 synthase (TxA 2 -S). 13, [15] [16] [17] [18] [19] Affs of rabbits infused with Ang II at a slow pressor rate have a decreased endothelium-dependent relaxation factor (EDRF) response to acetylcholine (ACh) and an increased contractile response to Ang II, but a normal response to NE. 6 Tempol corrects the defective relaxation to ACh and moderates the enhanced response to Ang II. One aim of the present study was to compare vasoconstrictor responsiveness of Affs of Ang II-infused rabbits with that to U-46 619 (TP-R agonist) and endothelin-1 (ET-1) and to determine the roles of O 2 Ϫ and the endothelium. A second aim was to investigate the role of TP-Rs. We compared responses from rabbits infused with Ang II at 200 and at 60 ng⅐kg Ϫ1 ⅐min Ϫ1 (Ang II 200 and 60) because Ang II 60 rabbits do not have hypertension, oxidative stress, or enhanced expression of mRNA for p22 phox in their Affs. 6 O 2 Ϫ can impair ACh-induced relaxation by bioinactivation of nitric oxide (NO) and generation of an endotheliumdependent contraction factor (EDCF) that depends on TP-R. 20 -28 Ligands for the TP-R include prostaglandin endoperoxides (PGH 2 ) generated by cyclooxygenase (COX) 1 and 2, TxA 2, isoprostanes (Iso) generated nonenzymatically by in-
Ϫ with arachidonate, and COX metabolites of hydroxyeicosatetraenoic acids. 29 We tested the hypothesis that endothelium-dependent generation of O 2
Ϫ and/or products activating TP-Rs mediate the EDCF response in Affs from rabbits infused with Ang II. We tested the role of O 2 Ϫ and Isos from the effects of tempol, of TP-R from ifetroban, 17 and COX-1, COX-2, and TxA 2 -S from the effects of paracoxib (P), SC-560 (SC), and OKY-046 (OKY), respectively. 30 -33 
Methods

Animal Protocols
The study was approved by the institutional Animal Care and Use Committee. Male New Zealand White rabbits (1.6 to 1.8 kg; nϭ104; Covance Inc., Denver, Pa) were maintained on standard chow (Na ϩ content 0.4 g⅐100 g Ϫ1 ). Rabbits (nϭ6 per group) were implanted subcutaneously with sterile osmotic minipumps (Alzet; DURET Corporation, Cupertino, Calif) to infusion vehicle (0.154 mol/L NaCl; Sham) or human Ang II (Peninsula Laboratories, San Carlos, Calif). All studies were performed under a protocol approved by the Georgetown University Animal Care and Use Committee.
Isolation and Microperfusion of Rabbit Afferent Arterioles
Rabbits were anesthetized with xylazine (10 mg⅐kg Ϫ1 intramuscularly), ketamine (50 mg⅐kg Ϫ1 intramuscularly), and pentobarbital sodium (10 mg⅐kg Ϫ1 intravenous), followed by heparin (1000 units intravenous) for anticoagulation. Microdissection and microperfusion of Aff was as described previously. 6, 10 Only arterioles showing basal tone and Ͼ50% contraction to NE at the beginning and end were selected. One Aff was used from each animal. Drugs were added to the bath.
Experimental Protocol
The first aim was to compare the contractile responses of Affs from Ang II 60 and Ang II 200 rabbits with sham rabbits (nϭ6 per group). Responses to superfusion with NE (10 Ϫ7 mol/L), Ang II (10 Ϫ8 mol/L), U-46 619 (10 Ϫ8 M, a TP-R agonist), or endothelin 1 (ET-1, 10 Ϫ8 mol/L) were related to a standard contraction with NE (10 Ϫ7 mol/L) plus 40 mmol/L KCl (NAK). Responses were maintained for 3 minutes and allowed to recover for 10 minutes. Because Affs from Ang II 60 rabbits had an enhanced response to Ang II, but normal responses to U-46 619 and ET-1, subsequent protocols with Ang II 60 rabbits were confined to the Ang II response.
The second aim was to evaluate the effects of blockade of TP-R on contractile responses. Affs were incubated for 30 minutes with ifetroban, which blocks completely contractions to U-46 619. 17, 34, 35 The protocol followed series 1 in a bath containing ifetroban (10 Ϫ6 mol/L). There were 3 groups of rabbits (nϭ6 per group).
The third aim was to evaluate the effects of metabolism of O 2 Ϫ on contractile responses. Affs were incubated for 20 minutes with tempol, which, at 10 Ϫ4 M, blocks fully the contractile responses to O 2
Ϫ generated by a quinolone or by prolonged administration of U-46 619. 31, 34 The protocol followed series 1 in a bath containing tempol (10 Ϫ4 mol/L). There were 3 groups of rabbits (nϭ6 per group).
The fourth aim was to evaluate the effects of TP-R blockade on contractile responses in Affs incubated with tempol. The protocol followed series 1 in arterioles preincubated for 20 to 30 minutes in a bath containing 10 Ϫ4 mol/L tempol and 10 Ϫ6 mol/L ifetroban. There were 3 groups of rabbits (nϭ6 per group).
The fifth aim was to contrast the effect of removal of the endothelium (EndoϪ) on responses to NE and Ang II of arterioles from sham and Ang II 200-infused rabbits. The endothelium was removed by luminal perfusion with compliment and an antibody to factor VIII, which prevents relaxation to acetylcholine (ACh) but not sodium nitroprusside. 10, 34 The sixth aim was to evaluate the effects of an SOD mimetic or an antagonist to COX-1 or COX-2 and TxA 2 -S or TP-R on EDCF responses to ACh of Affs from Ang II 200 rabbits. ACh given to preconstricted Affs from Ang II 200 rabbits caused constriction at Ͼ10 Ϫ5 mol/L. This indicated an EDCF. The EDRF response of Affs from normal rabbits is blocked by superfusion with a combination of N G -Nitro-L-arginine (LNNA) (10 Ϫ5 mol/L; NO synthase inhibitor) and 14,15 epoxyeicoa-5(Z)-enoic acid (EEZE) (10 Ϫ5 mol/L; epoxyeicosatrienoic acid antagonist). 35 Therefore, these EDCF studies (ACh 10 Ϫ6 to 10 Ϫ3 mol/L responses) were undertaken without preconstriction in vessels superfused with LNNA and EEZE. Subgroups were superfused with SC-560 (10 Ϫ7 mol/L) or paracoxib (10 Ϫ6 mol/L) to assess the contributions of COX-1 and COX-2, or with ifetroban (10 Ϫ6 mol/L) or OKY-046 (10 Ϫ5 mol/L) to assess the roles of TP-R and TxA 2 or with tempol (10 Ϫ4 mol/L) to assess the role of O 2 Ϫ and Isos.
Analysis of mRNA in Individual Isolated Afferent Arterioles
The methods for microdissection, mRNA extraction, and real-time polymerase chain reaction analysis have been published. 6, 36 The primers used for amplification of COX-1, COX-2, TP-R, and TxA 2 -S are shown in online Table I (available at http://circres.ahajournals. org). The amplified products were sequenced. The real-time polymerase chain reaction primers and probes were designed from the sequenced regions.
Drugs and Solutions
Solutions were prepared fresh daily. U-46 619 (Cayman Chemical, Ann Arbor, Mich) was evaporated under N 2 and reconstituted using 97% ethanol, and 55 mmol/L Tris purchased from Sigma (St. Louis, Mo). Earle deficient basal medium solution was used for dissections. It contains 8.89g⅐L Ϫ1 BME powder, 26 mol/L NaHCO 3 , 2 mmol/L L-glutamine, and 5% bovine serum albumin (5%; pH 7.40 to 7.45). MEM solution (10.1g MEM powder, 5 mol/L NaHCO 3 , 10 mmol/L HEPES, 14 mol/L NaOH, and 1 g glucose/L) containing 5% bovine serum albumin was used for perfusion and with 0.15% bovine serum albumin for superfusion. 6, 22 Tempol (4-hydroxy TEMPO), ACh, NE, LNNA, goat-antihuman F8-Rag antibody, guinea pig complement, and SC-560 were purchased from Sigma (St. Louis, Mo). Ifetroban (BMS-180291) was gift from Dr Martin Ogletree (Bristol Myers Squib, Princeton, NJ), paracoxib was from Pfizer-Pharmacia Pharmaceuticals, OKY-056 was from ONO Pharmaceutical, Osaka, Japan, and 14, 15-epoxyeicosa-5(Z)-enoic acid was from John R. Falck (University of Texas).
Calculations of Results and Statistics
The change of luminal diameter to an agonist (in series 1 to 5) was expressed as percent change compared with NAK (series 1 to 5), given by:
The change of luminal diameter to ACh (10 Ϫ6 to 10 Ϫ3 M, in series 6) was expressed as percent change compared with NE (10 Ϫ7 M), given by:
where C 0 is the basal diameter, C is the minimal diameter with NAK (series 1 to 5) or NE (aim 6), C 1 is the luminal diameter to agonist (series 1 to 5), and C 2 is the luminal diameter to ACh (series 6).
Statistical tests used 2-factor repeated-measures analysis of variance (ANOVA). When appropriate, post hoc comparisons between groups were made with Student t tests. Statistical significance with Bonferroni correction for 4 genes was PϽ0.05/4ϭ0.0125. 36 Data are presented as meanϮSD.
Results
The diameters of Affs were similar in the basal state (sham: 17 37 In series 1, Affs from Ang II 60 rabbits had a significantly enhanced contraction to Ang II (change in luminal diameter, Ϫ78Ϯ8% versus Ϫ43Ϯ9%; PϽ0.001) but a normal response to NE, U-46 619, and ET-1 (Figure 1 ). Affs from Ang II 200 rabbits had a normal response to NE but an enhanced response to Ang II (Ϫ110Ϯ10% versus Ϫ43Ϯ9%; PϽ0.001), U-46 619 (Ϫ89Ϯ8% versus Ϫ55Ϯ4%; PϽ0.01), and ET-1 (Ϫ110Ϯ10% versus Ϫ63Ϯ6%; PϽ0.001). Responses to Ang II, U-46 619, and ET-1 were significantly (PϽ0.001) greater than those from Ang II 60 rabbits.
In series 2, ifetroban did not affect the basal luminal diameter (17Ϯ1 m [vehicle] versus 18Ϯ2 m [ifetroban]; NS) or the change with NAK (Ϫ66Ϯ6% [vehicle] versus Ϫ61Ϯ6% [ifetroban]; NS) but abolished the response to U-46 619. Ifetroban did not modify contractile responses in sham rabbits ( Figure 2 ) or NE responses in Ang II 60 rabbits ( Figure 3 ) but normalized responses to Ang II in Ang II 60 Affs (sham: Ϫ43Ϯ9% versus Ϫ78Ϯ8% [Ang II 60 ϩ vehicle] versus 47Ϯ9% [Ang II 60 ϩ ifetroban]) ( Figure 3 ). Ifetroban did not modify responses to NE in Ang II 200 rabbits but blunted responses to Ang II (Ϫ85Ϯ8% versus Ϫ110.0Ϯ10%; PϽ0.01) and normalized responses to ET-1 (Ϫ80Ϯ8% versus Ϫ110Ϯ10%; PϽ0.001) (Figure 4) .
In series 3, tempol did not modify basal luminal diameter (18Ϯ1 m) or diameter during NAK (6Ϯ1 m). Tempol did not modify responses from sham rabbits ( Figure 2 ) or responses to NE or Ang II in Ang II 60 rabbits (Figure 3 ). However, tempol blunted responses to Ang II in Ang II 200 Affs (Ϫ62Ϯ8 versus Ϫ110Ϯ10; PϽ0.001) and normalized responses to U-46 619 (Ϫ60Ϯ6% versus Ϫ89Ϯ9%; PϽ0.001) and ET-1 (Ϫ59Ϯ7% versus Ϫ110Ϯ10%; PϽ0.001). During tempol, the luminal diameter responses to NE, U-46 619, and ET-1 did not differ significantly among the 3 groups of rabbits, but the response to Ang II in arterioles from Ang II 60 (Ϫ67Ϯ13%; Figure 3 ) and Ang II 200 rabbits (Ϫ62Ϯ8%; Figure 4 ) remained significantly greater than in arterioles from sham rabbits (Ϫ43Ϯ9%; PϽ0.01 versus Ang II rabbits). In series 4, ifetroban plus tempol did not modify the basal luminal diameters (18Ϯ1 m; NS) or the responses from sham-infused rabbits except to abolish the response to the U-46 619 (Figure 2 ). Tempol plus ifetroban added to arterioles from Ang II 60 rabbits, like ifetroban alone, normalized the response to Ang II (Figure 3) . When added to arterioles from Ang II 200 rabbits, the combination reduced the response to Ang II significantly more than tempol alone (Ϫ47Ϯ6% versus Ϫ62Ϯ8%; PϽ0.05) to values of shaminfused rabbits (Ϫ43Ϯ9%; NS). Ifetroban plus tempol, like tempol alone, normalized the response to ET-1.
In series 5, endothelium removal of arterioles from sham rabbits did not affect the basal diameter (18Ϯ1 m versus 17Ϯ1 m; PϭNS) or the response to NE but enhanced the response to Ang II (Endoϩ: Ϫ43Ϯ9% versus Endo: Ϫ69Ϯ8%; PϽ0.001) ( Figure 5 ). Addition of ifetroban or tempol to these EndoϪ arterioles did not modify the response to Ang II ( Figure 5 ). Endothelium removal of arterioles from Ang II 200 rabbits likewise did not modify the basal luminal diameter (17Ϯ1 m versus 17Ϯ2 m; PϭNS) or the response to NE but diminished the response to Ang II (Endoϩ: Ϫ110Ϯ10% versus EndoϪ: Ϫ96Ϯ3%; PϽ0.05) ( Figure 6 ). This was unaffected by ifetroban but was reduced further (Ϫ75Ϯ9%; PϽ0.05) by tempol to values not significantly different from the response to Ang II of de-endothelialized vessels of sham-infused rabbits (Ϫ69Ϯ10%; NS).
In series 6, the abundance of mRNA in individual afferent arterioles from Ang II 200 rabbits for COX-1 and TP-R was unchanged but was increased 2.6-fold for COX-2 (PϽ0.01; Table II ). The mRNA for TxA2-S was less than the limit for quantification. Affs from Ang II 200 rabbits had an impaired EDRF response and a contractile response to higher concentration of ACh that was abolished by endothelium removal (Figure 7A ). This EDCF response was analyzed further in vessels without preconstriction and with EDRF/NO and endothelium-derived hyperpolarizing factor responses blocked with LNNA plus EEZE. 10 These vessels demonstrated a graded contractile response to ACh that was not present in vessels from Sham rabbits (Ϫ42Ϯ4% versus Ϫ5Ϯ3% in sham, PϽ0.001). This was abolished by removing the endothelium ( Figure 7B ). The contractile response was reduced by bath addition of tempol ( Figure 7B ), SC-560 ( Figure 7C ), or OKY-046 ( Figure 7D ) and was abolished by bath addition of paracoxib ( Figure 7C ) or ifetroban ( Figure 7D ).
Discussion
The main new findings of this study are that Affs from rabbits infused at a nonpressor rate of Ang II that does not cause oxidative stress or endothelial dysfunction have a selective increase in the response to Ang II. This is normalized by a TP-R antagonist. Affs from rabbits infused at a rate that increases MAP by 38 mm Hg over 12 days and causes oxidative stress and enhanced expression of p22 phox have enhanced responses to Ang II, U-46 619, and ET-1 but not to NE. A TP-R antagonist and a SOD mimetic together are required to normalize the Ang II response in Ang II 200 arterioles. 6 Endothelium removal enhanced Ang II responses of Affs from sham rabbits but blunted it in those from Ang II 200 rabbits. Ifetroban was ineffective after endothelium removal. Affs from Ang II 200 rabbits have a 2.6-fold increase in the mRNA for COX-2 and an EDCF response to ACh that is reduced by an antagonist to COX-1 or TxA 2 -S or by an SOD mimetic, but is prevented fully by an antagonist to COX-2 or TP-R.
U-46 619 superfused over Affs from normal rabbits for a longer period of 15 to 20 minutes causes contractions that are moderated by NO and are promoted by O 2 Ϫ . 34 Therefore, the duration of agonist exposure was limited in this series to obviate these effects in normal vessels.
The present study confirms that infusion of Ang II at a slow pressor rate enhances responses of Affs to Ang II and shows further that there is an enhanced response to U-46 619 and ET-1, but not to NE alone or NE plus high [K ϩ ]. 6 The preservation of responses to NE is unexplained but suggests that the enhanced vascular reactivity to Ang II, U-46 619, and ET-1 is not likely to be secondary to structural vascular amplification. 38
Role of O 2
؊
Oxidative stress in large vessels activates phospholipase A 2. 11 and TxA 2 -S and enhances the responses to TP-R activation, 20, 21, 25, 27, 39 likely by stabilizing the beta isoform of the TP-R. 40 Furthermore, oxidative stress generates ET-1 in vascular smooth muscle cells (VSMCs). 41 The present study shows that oxidative stress enhances the contractile responses of the major resistance vessel of the kidney not only to a TP-R agonist but also to Ang II and ET-1.
Antioxidants prevent enhanced endothelin generation in rats infused with slow pressor Ang II. 9 Activation of endothelin and TP-Rs enhance myogenic constriction in VSMCs from hypertensive animals. 42, 43 Ang II infusion upregulates Ca ϩϩ channel activity in blood vessels, whereas antioxidants improve VSMC Ca ϩϩ uptake into the sarcoplasmic reticulum in animals with oxidative stress. 43, 44 The finding that Affs from Ang II 200 rabbits have exaggerated responses to Ang II, U-46 619, and ET-1 that are partially or fully corrected by tempol and that the effects of tempol survive de-endothelialization indicate that oxidative stress increases the reactivity of the renal afferent arteriole VSCMs to a number of agonists. However, there is selectivity because responses to NE and high [K ϩ ] are unaffected.
Role of TP Receptors
The identified ligands for TP-Rs are PGH 2 , TxA 2 , Isos such as 8-Iso-PGF 2␣ , COX metabolites of HETEs, and the stable agonist U-46 619. 1, 29 Ang II infusion activates phospholipase A 2 (PLA 2 ) and increases expression of COX-2 in VSMCs. In contrast, COX-2 in the macula densa is suppressed. [45] [46] [47] Ang II also increases the generation of TxA 2 and 8-Iso PGF 2␣ . 11, 12, 14, 48 The present study demonstrates that Ang II 200 upregulates the mRNA for COX-2 in Affs. Thus, an Ang II infusion likely increases all the endogenous ligands for the TP-R in the Aff. Moreover, oxidative stress enhances vasoconstriction to PGH 2 . 27 The importance of these TP-R ligands in the response to Ang II is apparent from the effect of an antagonist of TxA 2 -S or TP-R, or deletion of the gene for TP-R, to moderate or prevent hypertension and renal vasoconstriction during a slow pressor response to Ang II. 15, 18, 19, 49 The effect of ifetroban to normalize responses to Ang II in Ang II 60 Affs can be dissociated from O 2 Ϫ because these rabbits do not have increased lipid peroxidation or increased NADPH oxidase activity in their kidneys or increased mRNA expression for p22 phox in their Affs. 6 Moreover, incubation of Affs from Ang II 60 or Ang II 200 rabbits with tempol did not moderate the effect of ifetroban to blunt contraction to Ang II. Presumably the ligand for the TP-R is not an Iso but a COX metabolite.
Ifetroban blunted the response to Ang II and to ET-1 in arterioles from Ang II 200 rabbits. ET-1 releases PGH 2 and/or TxA 2 from VSMCs of the rat, from damaged coronary arteries of the pig, and from postischemic rat heart. 37, 42, 50 A component of renal microvascular contraction during prolonged Ang II-induced hypertension entails generation of ET-1 with release of PGH 2 and TxA 2 that activate TP-Rs on VSMCs.
Role of Endothelium
A novel finding is that the afferent arteriolar responses to Ang II depend on the endothelium. Endothelium removal increased contractile responses to Ang II by Ϸ40% in normal arterioles, likely reflecting NO generation. 51 In contrast, endothelium removal reduced Ang II responses in vessels from Ang II 200 rabbits and prevented the blunting of the Ang II response by ifetroban, but not tempol. Thus, Ang II releases an EDCF from the endothelium of these vessels. This
